Abstract
Osteosarcoma (OS) is a disease that afflicts teenagers and adolescents in the prime of their lives. In spite of surgery and therapies currently used, there is a 1/3 chance of relapse. As for other cancers, current research is largely devoted to elucidating the molecular basis of the disease, with the anticipation that such research will lead to discovery and development of biological therapies. The major advantage of utilising such therapy is the relative lack of toxicity to normal tissues. One such enterprising candidate molecule, pigment epithelium-derived factor (PEDF), has recently been implicated to be involved in control of OS in orthotopic spontaneously metastasising models of the disease, whether administered as recombinant protein, overexpressed or administered as short peptides derived from the parent molecule. Expression of PEDF is inversely proportional to expression of vascular endothelial growth factor (VEGF) at the growth plate cartilage layer of growing bone in both mice and man. PEDF, originally discovered for its potent antiangiogenic activity, is now established as an anticancer factor with multiple mechanisms at its disposal for tumour inhibition. Current efforts are devoted to develop drug delivery systems, such as controlled release nanoparticles, that can be used to progress this potential drug candidate closer towards clinical trials for OS.
Keywords: PEDF, VEGF, osteosarcoma, tumour, angiogenesis, drug delivery, peptide, therapy
Current Cancer Drug Targets
Title: PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Volume: 8 Issue: 8
Author(s): Crispin R. Dass, Eugene T.H. Ek and Peter F.M. Choong
Affiliation:
Keywords: PEDF, VEGF, osteosarcoma, tumour, angiogenesis, drug delivery, peptide, therapy
Abstract: Osteosarcoma (OS) is a disease that afflicts teenagers and adolescents in the prime of their lives. In spite of surgery and therapies currently used, there is a 1/3 chance of relapse. As for other cancers, current research is largely devoted to elucidating the molecular basis of the disease, with the anticipation that such research will lead to discovery and development of biological therapies. The major advantage of utilising such therapy is the relative lack of toxicity to normal tissues. One such enterprising candidate molecule, pigment epithelium-derived factor (PEDF), has recently been implicated to be involved in control of OS in orthotopic spontaneously metastasising models of the disease, whether administered as recombinant protein, overexpressed or administered as short peptides derived from the parent molecule. Expression of PEDF is inversely proportional to expression of vascular endothelial growth factor (VEGF) at the growth plate cartilage layer of growing bone in both mice and man. PEDF, originally discovered for its potent antiangiogenic activity, is now established as an anticancer factor with multiple mechanisms at its disposal for tumour inhibition. Current efforts are devoted to develop drug delivery systems, such as controlled release nanoparticles, that can be used to progress this potential drug candidate closer towards clinical trials for OS.
Export Options
About this article
Cite this article as:
Dass R. Crispin, Ek T.H. Eugene and Choong F.M. Peter, PEDF as an Emerging Therapeutic Candidate for Osteosarcoma, Current Cancer Drug Targets 2008; 8 (8) . https://dx.doi.org/10.2174/156800908786733487
DOI https://dx.doi.org/10.2174/156800908786733487 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design MicroRNA Regulation of TRAIL in Renal Carcinoma: Tiny Juggernauts at Work
Current Molecular Pharmacology Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Analytical Methods for Determination of CO and CO2 and their Applicability in Biological Studies
Current Pharmaceutical Analysis Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Patent Selections
Recent Patents on Biomarkers TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Natural Polymers Based Hydrogels for Cell Culture Applications
Current Medicinal Chemistry Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Current Gene Therapy Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Cancer and Treatment Modalities
Current Cancer Therapy Reviews Baculovirus Gene Delivery: A Flexible Assay Development Tool
Current Gene Therapy Licochalcone B Arrests Cell Cycle Progression and Induces Apoptosis in Human Breast Cancer MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery Targeted Drug Delivery in Brain Tumors-nanochemistry Applications and Advances
Current Topics in Medicinal Chemistry P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets